LaunchPad ImprimisRx Debuts Fortisite Compounded Antibiotic Formulation By Staff Monday, October 3, 2022 12:11 AM Product: Fortisite Top Line: ImprimisRx announced the availability of Fortisite, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%. Close Up: Compounded topical antibiotic formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. Fortisite, which includes a compounded combination antibiotic formulation (Tobramycin 1.5% and Vancomycin 5%) in solution, is tested for both potency and sterility before it is dispensed, and uniquely, is stable at refrigerated temperatures (5°C) for up to 180 days. Fortisite formulations are currently available for individual patients through the ImprimisRx 503A national mail order pharmacy. Once available through the ImprimisRx FDA-registered and FDA inspected 503B outsourcing facility, which is expected in the first half of 2023, physicians will be able, for the first time, to stock a fortified or high-concentration compounded antibiotic in their offices for the immediate treatment of patients-in-need. In addition, consistent with its commitment to patient access, ImprimisRx will provide a robust Patient Access Program and a 100% replacement guarantee for any expired 503B Fortisite product, ensuring all U.S. eyecare professionals can continuously stock Fortisite formulations in their offices without the additional expense associated with expired product replacement. Vital Stats: To order Fortisite online, go to ImprimisRx.com/fortified, or call ImprimisRx Customer Care at 844 446 6979. Same-day shipping is currently available Monday through Friday for patients if a complete prescription is received by 12pm PT (3pm ET).